Amphivena Therapeutics

24 articles about Amphivena Therapeutics

• Amphivena Presents New Monotherapy and First Combination Therapy Clinical Data in Solid Tumor Patients

  6/4/2021

  Investigational Drug Candidate AMV564 Demonstrates Safety with Evidence of Anti-tumor T cell Expansion and One Complete Response, Multiple Mixed Responses and Durable Disease Stabilization in Solid Tumor Patients

• Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting

  4/12/2021

  Cytokine data from cancer patients reveal a unique profile for AMV564 therapy, with strong induction of IFNγ and other cytokines and chemokines that drive T cell activation and trafficking, and limited levels of IL6. As MDSC produce IL6 and other cytokines that promote cytokine release syndrome (CRS), these findings are consistent with our observations of limited CRS with AMV564 treatment.

• Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564

  12/16/2020

  Amphivena Therapeutics , a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that

• Novel AML patient selection assay for AMV564, Amphivena's lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting

  12/6/2020

  Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, presented data on a novel assay for selection of acute myeloid leukemia patients for treatment with AMV564, at the 62nd Annual American Society of Hematology Meeting and Exposition, taking place virtually from December 5-8, 2020.

• Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/9/2020

  AMV564, a novel first-in-class agent that depletes MDSC and activates T cells, is being investigated in a Phase 1 clinical trial in advanced solid tumors

• Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564 at the AACR 2020 Virtual Annual Meeting II

  6/23/2020

  Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity, today presents translational data for the lead clinical candidate from its ReSTORE (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers, AMV564, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.

• Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference

  5/29/2020

  Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immunotherapeutics that restore anti-cancer immunity to the patient, today announced that Curtis Ruegg , Ph.D., President and CEO, will present a company overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020

• Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020

  5/29/2020

  Initial data from the Phase 1 dose escalation trial in 18 patients with advanced solid tumors shows AMV564 administered subcutaneously was well tolerated, with no dose-limiting toxicities

• Amphivena Reports Data on Phase 1 Study of AMV564 at Ash Annual Meeting

  12/9/2019

  Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented at the American Society of Hematology annual meeting data from a Phase 1 study of its bivalent T cell engager clinical candidate, AMV564.

• Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer

  12/2/2019

  The company’s Founder and current President and Chief Executive Officer, Jeanmarie Guenot, Ph.D., will transition into an Advisory role.

• Rationale for Expansion of AMV564 Into Solid Tumors

  11/7/2019

  Selectivity of AMV564 Presents Opportunity in Patients with Solid Tumors

• Amphivena Initiates Solid Tumor Clinical Trial

  10/16/2019

  Amphivena to advance AMV564 in a Multi-Center Dose Finding Phase 1 Clinical Study in Patients with Solid Tumors

• Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio

  9/24/2019

  The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and insiders MPM Capital, funds managed by Tekla Capital Management LLC and Franklin Berger.

• Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting

  7/1/2019

  The oral presentation of data from 33 patients treated within 9 cohorts demonstrated that AMV564 is active in relapsed or refractory AML and expanded upon the data from 26 patients presented at the Annual Meeting of the American Society of Hematology in December 2018.

• 

  BioSpace Movers and Shakers: March 8

  3/8/2019

  Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.

• Amphivena Expands Executive Team

  3/5/2019

  Victoria Smith, Ph.D. Named Chief Scientific Officer; Peter Van Vlasselaer, Ph.D. Appointed Executive Chairman of the Board

• Amphivena Presents at ASH First-in-Human Phase 1 Clinical Data on AMV564

  12/3/2018

  Data Demonstrate AMV564’s Safety, Anti-Leukemic Activity, and Unique PK Profile

• Amphivena Demonstrates at EHA First Human Proof-of-Concept For AMV564 in Relapsed/Refractory AML

  6/15/2018

  The data demonstrates that AMV564 engages and activates T cells resulting in leukemic cytoreduction.

• Amphivena Presents Preclinical Data at ASH That Points to a Potentially New Treatment for MDS Patients

  12/9/2017

  Amphivena plans to launch a Phase 1 clinical study in patients with MDS in early 2018.

• Amphivena Receives Orphan Drug Designation for AMV564, a Novel CD33/CD3 T-Cell Engagement Therapy for the Treatment of Acute Myeloid Leukemia

  11/29/2017

  Amphivena is conducting a Phase 1 clinical study of AMV564 in relapsed or refractory AML.